Results 1 to 10 of about 550 (87)

Evolutionary accumulation of FKS1 mutations from clinical echinocandin-resistant Candida auris

Emerging Microbes and Infections
Introduction: Drug resistance to echinocandins, first-line drugs used to treat Candida auris infection, is rapidly emerging. However, the accumulation of mutations in genes other than FKS1 (before an isolate develops to resistance via FKS1 mutations ...
Hong Shang, Sufei Tian
exaly   +3 more sources

Decreased echinocandin susceptibility in Candida parapsilosis causing candidemia and emergence of a pan-echinocandin resistant case in China

Emerging Microbes and Infections, 2023
Candida parapsilosis is becoming a predominant non-albicans cause of invasive candidiasis (IC). Echinocandins are the preferred choice for IC treatment and prophylaxis. Resistance to echinocandins in C.
Minya Lu, Fushun Li
exaly   +3 more sources

Multifactorial Role of Mitochondria in Echinocandin Tolerance Revealed by Transcriptome Analysis of Drug-Tolerant Cells

mBio, 2021
Fungal infections cause significant mortality and morbidity worldwide, and the limited existing antifungal reservoir is further weakened by the emergence of strains resistant to echinocandins, a first line of antifungal therapy.
Rocio Garcia-Rubio, Cristina Jimenez-Ortigosa, Lucius DeGregorio, Christopher Quinteros, Erika Shor, David S. Perlin   +5 more
doaj   +1 more source

Curcumin Epigenetically Represses Histone Acetylation of Echinocandin B Producing Emericella rugulosa

Physiologia, 2023
Echinocandin B is a natural product that possesses potent antifungal property against a wide array of fungi. This antifungal agent is produced by Emericella rugulosa. The biosynthetic genes of echinocandin B are physically organized in two gene clusters (
Vandana Kumari, Vinay Kumar, Manisha Kaushal, Antresh Kumar   +3 more
doaj   +1 more source

Loss of Septation Initiation Network (SIN) kinases blocks tissue invasion and unlocks echinocandin cidal activity against Aspergillus fumigatus.

PLoS Pathogens, 2021
Although considered effective treatment for many yeast fungi, the therapeutic efficacy of the echinocandin class of antifungals for invasive aspergillosis (IA) is limited.
Ana Camila Oliveira Souza, Adela Martin-Vicente, Ashley V Nywening, Wenbo Ge, David J Lowes, Brian M Peters, Jarrod R Fortwendel   +6 more
doaj   +1 more source

Whole genome analysis of echinocandin non-susceptible Candida Glabrata clinical isolates: a multi-center study in China

BMC Microbiology, 2023
Background Candida glabrata is an important cause of invasive candidiasis. Echinocandins are the first-line treatment of invasive candidiasis caused by C. glabrata.
Yi Li, Xin Hou, Ruoyu Li, Kang Liao, Ling Ma, Xiaoming Wang, Ping Ji, Haishen Kong, Yun Xia, Hui Ding, Wei Kang, Ge Zhang, Jin Li, Meng Xiao, Yingxing Li, Yingchun Xu   +15 more
doaj   +1 more source

Post-Prescription Audit Plus Beta-D-Glucan Assessment Decrease Echinocandin Use in People with Suspected Invasive Candidiasis

Medicina, 2021
Background and Objectives: Overtreatment with antifungal drugs is often observed. Antifungal stewardship (AFS) focuses on optimizing the treatment for invasive fungal diseases.
Rita Murri, Sara Lardo, Alessio De Luca, Brunella Posteraro, Riccardo Torelli, Giulia De Angelis, Francesca Giovannenze, Francesco Taccari, Lucia Pavan, Lucia Parroni, Maurizio Sanguinetti, Massimo Fantoni   +11 more
doaj   +1 more source

Global analysis of the evolution and mechanism of echinocandin resistance in Candida glabrata. [PDF]

PLoS Pathogens, 2012
The evolution of drug resistance has a profound impact on human health. Candida glabrata is a leading human fungal pathogen that can rapidly evolve resistance to echinocandins, which target cell wall biosynthesis and are front-line therapeutics for ...
Sheena D Singh-Babak, Tomas Babak, Stephanie Diezmann, Jessica A Hill, Jinglin Lucy Xie, Ying-Lien Chen, Susan M Poutanen, Robert P Rennie, Joseph Heitman, Leah E Cowen   +9 more
doaj   +1 more source

Efficacy of Trimethoprim–Sulfamethoxazole in Combination with an Echinocandin as a First-Line Treatment Option for Pneumocystis Pneumonia: A Systematic Review and Meta-Analysis

Antibiotics, 2022
Although combination therapy using trimethoprim–sulfamethoxazole (TMP–SMX) plus echinocandins has been reported to reduce the mortality of patients with pneumocystis pneumonia (PCP), it remains unclear whether it is more effective than TMP–SMX ...
Hideo Kato, Mao Hagihara, Nobuhiro Asai, Takumi Umemura, Yuichi Shibata, Jun Hirai, Yuka Yamagishi, Takuya Iwamoto, Hiroshige Mikamo   +8 more
doaj   +1 more source

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum

Microorganisms, 2021
Candida auris is an emerging and frequently multidrug-resistant pathogen against which the echinocandins are the preferred therapeutic option. We compared killing activities of anidulafungin, caspofungin, micafungin, and rezafungin against 13 isolates ...
Renátó Kovács, Zoltán Tóth, Jeffrey B. Locke, Lajos Forgács, Gábor Kardos, Fruzsina Nagy, Andrew M. Borman, László Majoros   +7 more
doaj   +1 more source